From pathways to people: Applying the adverse outcome pathway (AOP) for skin sensitization to risk assessment

Altex

Volumn 30, Issue 4, 2013, Pages 473-486

  MacKay, Cameron ^a   Davies, Michael ^a   Summerfield, Vicki ^a   Maxwell, Gavin ^a  

^a UNILEVER RESEARCH   (United Kingdom)

Author keywords

Adverse outcome pathway; Models; Skin sensitization; Toxicodynamics; Toxicokinetics

Indexed keywords

PROTEIN;

ADVERSE OUTCOME PATHWAY; ARTICLE; CD8+ T LYMPHOCYTE; CONCEPTUAL FRAMEWORK; COVALENT BOND; HAZARD ASSESSMENT; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PARTITION COEFFICIENT; PHYSICAL CHEMISTRY; PROTEIN MODIFICATION; RISK ASSESSMENT; SKIN ALLERGY; SKIN SENSITIZATION; STRATUM CORNEUM; TOXICOKINETICS;

ANIMAL TESTING ALTERNATIVES; ANIMALS; DERMATITIS, ALLERGIC CONTACT; HUMANS; MODELS, BIOLOGICAL; PROTEIN BINDING; RISK ASSESSMENT; TOXICITY TESTS;

EID: 84893067014     PISSN: 1868596X     EISSN: 18688551     Source Type: Journal    
DOI: 10.14573/altex.2013.4.473     Document Type: Article

References (113)

1. Adler, S., Basketter, D., Creton, S., et al. (2011). Alternative (non-animal) methods for cosmetics testing: current status and future prospects - 2010. Arch Toxicol 85, 367-485.
2. Ahmed, R., Bevan, M. J., Reiner, S. L., et al. (2009). The precursors of memory: models and controversies. Nat Rev Immunol 9, 662-668.
3. Ahmed, R. and Akondy, R. S. (2011). Insights into human CD8(+) T-cell memory using the yellow fever and smallpox vaccines. Immunol Cell Biol 89, 340-345.
4. Alden, K., Read, M., Timmis, J., et al. (2013). Spartan: A comprehensive tool for understanding uncertainty in simulations of biological systems. PLoS Comput Biol 9, e1002916.
5. Andersen, M. E. (2003). Toxicokinetic modeling and its applications in chemical risk assessment. Toxicol Lett 138, 9-27.
6. Andrews, P. S., Polack, F. A. C., Sampson, A.T., et al. (2010). The CoSMoS process, version 0.1: a process for the modelling and simulation of complex systems. University of York Technical Report YCS - 2010, 453.
7. Ankley, G. T., Bennett, R. S., Erickson, R. J., et al. (2010). Adverse outcome pathways: a conceptual framework to support ecotoxicology research and risk assessment. Environ Toxicol Chem 29, 730-741.
8. Antia, R., Bergstrom, C. T., Pilyugin, S. S., et al. (2003). Models of CD8+ responses: 1. What is the antigen-independent proliferation program. J Theor Biol 221, 585-598.
9. Api, A. M., Basketter, D. A., Cadby, P. A., et al. (2008). Dermal sensitization quantitative risk assessment (QRA) for fragrance ingredients. Regul Toxicol Pharmacol 52, 3-23.
10. Ashauer, R., Agatz, A., Albert, C., et al. (2011). Toxicokinetic- toxicodynamic modeling of quantal and graded sublethal endpoints: a brief discussion of concepts. Environ Toxicol Chem 30, 2519-2524.
11. Asquith, B. and Bangham, C. R. M. (2003). An introduction to lymphocyte and viral dynamics: the power and limitations of mathematical analysis. Proc R Soc Lond B Biol Sci 270, 1651-1657.
12. Asquith, B. and Bangham, C. R. M. (2007). Quantifying HTLV-I dynamics. Immunol Cell Biol 85, 280-286.
13. Basketter, D., Dooms-Goossens, A., Karlberg, A. T., et al. (1995). The chemistry of contact allergy: why is a molecule allergenic? Contact Dermatitis 32, 65-73.
14. Basketter, D. A., Evans, P., Fielder, R. J., et al. (2002). Local lymph node assay - validation, conduct and use in practice. Food Chem Toxicol 40, 593-598.
15. Basketter, D., Pease, C., Kasting, G., et al. (2007). Skin sensitisation and epidermal disposition: the relevance of epidermal disposition for sensitisation hazard identification and risk assessment. The report and recommendations of ECVAM workshop 59. Altern Lab Anim 35, 137-154.
16. Basketter, D. A. and Kimber, I. (2010). Contact Hypersensitivity (397-411). In C. A. McQueen (ed.), Comprehensive Toxicology. Elsevier.
17. Bauch, C., Kolle, S. N., Ramirez, T., et al. (2012). Putting the parts together: combining in vitro methods to test for skin sensitizing potentials. Regul Toxicol Pharmacol 63, 489-504.
18. Bauer, B., Andersson, S. I., Stenfeldt, A.-L., et al. (2011). Modification and expulsion of keratins by human epidermal keratinocytes upon hapten exposure in vitro. Chem Res Toxicol 24, 737-743.
19. Ben Dror, L., Barnea, E., Beer, I., et al. (2010). The HLA-B*2705 peptidome. Arthritis Rheum 62, 420-429.
20. Bhattacharya, S., Conolly, R. B., Kaminski, N. E., et al. (2010). A bistable switch underlying B-cell differentiation and its disruption by the environmental contaminant 2,3,7,8-tetrachlorodibenzo-p-dioxin. Toxicol Sci 115, 51-65.
21. Bhattacharya, S., Zhang, Q., Carmichael, P. L., et al. (2011). Toxicity testing in the 21 century: defining new risk assessment approaches based on perturbation of intracellular toxicity pathways. PloS One 6, e20887.
22. Bocharov, G. A. (1998). Modelling the dynamics of LCMV infection in mice: conventional and exhaustive CTLresponses. J Theor Biol 192, 283-308.
23. Bocharov, G., Klenerman, P., and Ehl, S. (2003). Modelling the dynamics of LCMV infection in mice: II. Compartmental structure and immunopathology. J Theor Biol 221, 349-378.
24. Böhme, A., Thaens, D., Paschke, A., et al. (2009). Kinetic glutathione chemoassay to quantify thiol reactivity of organic electrophiles - application to alpha,beta-unsaturated ketones, acrylates, and propiolates. Chem Res Toxicol 22, 742-750.
25. Bonnist, E. Y. M., Gorce, J.-P., Mackay, C., et al. (2011). Measuring the penetration of a skin sensitizer and its delivery vehicles simultaneously with confocal Raman spectroscopy. Skin Pharmacol Physiol 24, 274-283.
26. Boroujerdi, M. (2001). Pharmacokinetics: Principles and Applications. New York, USA: McGraw-Hill Inc.
27. Butler, N. S., Nolz, J. C., and Harty, J. T. (2011). Immunologic considerations for generating memory CD8 Tcells through vaccination. Cell Microbiol 13, 925-933.
28. Carreño, L. J., González, P. A., and Kalergis, A. M. (2006). Modulation of Tcell function by TCR/pMHC binding kinetics. Immunobiology 211, 47-64.
29. Chao, D. L., Davenport, M. P., Forrest, S., et al. (2004). A stochastic model of cytotoxic Tcell responses. J Theor Biol 228, 227-240.
30. Chipinda, I., Ajibola, R. O., Morakinyo, M. K., et al. (2010). Rapid and simple kinetics screening assay for electrophilic dermal sensitizers using nitrobenzenethiol. Chem Res Toxicol 23, 918-925.
31. Christensson, J. B., Matura, M., Gruvberger, B., et al. (2010). Linalool - a significant contact sensitizer after air exposure. Contact Dermatitis 62, 32-41.
32. Dancik, Y., Miller, M. A., Jaworska, J., et al. (2013). Design and performance of a spreadsheet-based model for estimating bioavailability of chemicals from dermal exposure. Adv Drug Delivery Rev 65, 221-236.
33. Davies, M., Pendlington, R. U., Page, L., et al. (2011). Determining epidermal disposition kinetics for use in an integrated nonanimal approach to skin sensitization risk assessment. Toxicol Sci 119, 308-318.
34. Felter, S. P., Robinson, M. K., Basketter, D. A., et al. (2002). A review of the scientific basis for uncertainty factors for use in quantitative risk assessment for the induction of allergic contact dermatitis. Contact Dermatitis 47, 257-266.
35. Felter, S. P., Ryan, C. A., Basketter, D. A., et al. (2003). Application of the risk assessment paradigm to the induction of allergic contact dermatitis. Regul Toxicol Pharmacol 37, 1-10.
36. Gebreselassie, D., Spiegel, H., and Vukmanovic, S. (2006). Sampling of major histocompatibility complex class I-associated peptidome suggests relatively looser global association of HLA-B*5101 with peptides. Hum Immunol 67, 894-906.
37. Gibbs, S., van de Sandt, J. J. M., Merk, H. F., et al. (2007). Xenobiotic metabolism in human skin and 3D human skin reconstructs: a review. Curr Drug Metab 8, 758-772.
38. Gill, C., Parkinson, E., Church, M. K., et al. (2011). A qualitative and quantitative proteomic study of human microdialysate and the cutaneous response to injury. AAPS J 13, 309-317.
39. Götz, C., Pfeiffer, R., Tigges, J., et al. (2012). Xenobiotic metabolism capacities of human skin in comparison with a 3D-epidermis model and keratinocyte-based cell culture as in vitro alternatives for chemical testing: phase II enzymes. Exp Dermatol 21, 364-369.
40. Hagvall, L., Baron, J. M., Börje, A., et al. (2008). Cytochrome P450-mediated activation of the fragrance compound geraniol forms potent contact allergens. Toxicol Appl Pharmacol 233, 308-313.
41. Herkenne, C., Alberti, I., Naik, A., et al. (2008). In vivo methods for the assessment of topical drug bioavailability. Pharm Res 25, 87-103.
42. Hickman, H. D., Luis, A. D., Buchli, R., et al. (2004). Toward a definition of self: proteomic evaluation of the class I peptide repertoire. J Immunol 172, 2944-2952.
43. Holmgaard, R., Nielsen, J. B., and Benfeldt, E. (2010). Microdialysis sampling for investigations of bioavailability and bioequivalence of topically administered drugs: current state and future perspectives. Skin Pharmacol Physiol 23, 225-243.
44. Hoof, I., van Baarle, D., Hildebrand, W. H., et al. (2012). Proteome sampling by the HLA class I antigen processing pathway. PLoS Comput Biol 8, e1002517.
45. Ibrahim, R., Nitsche, J. M., and Kasting, G. B. (2012). Dermal clearance model for epidermal bioavailability calculations. J Pharm Sci 101, 2094-2108.
46. Jacques, C., Perdu, E., Duplan, H., et al. (2010). Disposition and biotransformation of 14C-Benzo(a)pyrene in a pig ear skin model: ex vivo and in vitro approaches. Toxicol Lett 199, 22-33.
47. Jaworska, J., Harol, A., Kern, P. S., et al. (2011). Integrating non-animal test information into an adaptive testing strategy - skin sensitization proof of concept case. ALTEX 28, 211-225.
48. Jaworska, J., Dancik, Y., Kern, P., et al. (2013). Bayesian integrated testing strategy to assess skin sensitization potency: from theory to practice. J Appl Toxicol May 14. doi: 10.1002/jat.2869 (Epub ahead of print).
49. Johnson, K. L., Ovsyannikova, I. G., Mason, C. J., et al. (2009). Discovery of naturally processed and HLA-presented class I peptides from vaccinia virus infection using mass spectrometry for vaccine development. Vaccine 28, 38-47.
50. Jowsey, I. R., Basketter, D. A., Westmoreland, C., et al. (2006). A future approach to measuring relative skin sensitising potency: a proposal. J Appl Toxicol 26, 341-350.
51. Judson, R. S., Kavlock, R. J., Setzer, R. W., et al. (2011). Estimating toxicity-related biological pathway altering doses for high-throughput chemical risk assessment. Chem Res Toxicol 24, 451-462.
52. Kaech, S. M. and Ahmed, R. (2001). Memory CD8+ Tcell differentiation: initial antigen encounter triggers a developmental program in naïve cells. Nat Immunol 2, 415-422.
53. Kaech, S. M. and Cui, W. (2012). Transcriptional control of effector and memory CD8+ Tcell differentiation. Nat Rev Immunol 12, 749-761.
54. Karlberg, A.-T., Bergström, M. A., Börje, A., et al. (2008). Allergic contact dermatitis - formation, structural requirements, and reactivity of skin sensitizers. Chem Res Toxicol 21, 53-69.
55. Kimber, I., Gerberick, G. F., and Basketter, D. A. (1999). Thresholds in contact sensitization: theoretical and practical considerations. Food Chem Toxicol 37, 553-560.
56. Kimber, I. and Dearman, R. J. (2002). Allergic contact dermatitis: the cellular effectors. Contact Dermatitis 46, 1-5.
57. Kimber, I. and Dearman, R. J. (2003). What makes a chemical an allergen? Ann Allergy Asthma Immunol 90, 28-31.
58. Kimber, I., Basketter, D. A., Gerberick, G. F., et al. (2011). Chemical allergy: translating biology into hazard characterization. Toxicol Sci 120, Suppl, S238-268.
59. Kimber, I., Maxwell, G., Gilmour, N., et al. (2012). Allergic contact dermatitis: a commentary on the relationship between Tlymphocytes and skin sensitising potency. Toxicology 291, 18-24.
60. Krewski, D., Acosta, D., Andersen, M., et al. (2010). Toxicity testing in the 21st century: a vision and a strategy. J Toxicol Environ Health Part B Crit Rev 13, 51-138.
61. Landsteiner, K. and Di Somma, A. A. (1938). Studies on the sensitization of animals with simple chemical compounds : V. sensitisation to diazomethane and mustard oil. J Exp Med 68, 505-512.
62. Lau, C., Andersen, M. E., Crawford-Brown, D. J., et al. (2000). Evaluation of biologically based dose-response modeling for developmental toxicity: a workshop report. Regul Toxicol Pharmacol 31, 190-199.
63. Lepoittevin, J. P., Basketter, D. A., Goossens, A., et al. (eds.) (2011). Allergic Contact Dermatitis: The Molecular Basis. Berlin, Germany: Springer.
64. Louisse, J., de Jong, E., van de Sandt, J. J. M., et al. (2010). The use of in vitro toxicity data and physiologically based kinetic modeling to predict dose-response curves for in vivo developmental toxicity of glycol ethers in rat and man. Toxicol Sci 118, 470-484.
65. Magnusson, B. M., Anissimov, Y. G., Cross, S. E., et al. (2004). Molecular size as the main determinant of solute maximum flux across the skin. J Invest Dermatol 122, 993-999.
66. Martin, S. and Weltzien, H. U. (1994). Tcell recognition of haptens, a molecular view. Int Arch Allergy Immunol 104, 10-16.
67. Martin, S., Lappin, M. B., Kohler, J., et al. (2000). Peptide immunization indicates that CD8+ Tcells are the dominant effector cells in trinitrophenyl-specific contact hypersensitivity. J Invest Dermatol 115, 260-266.
68. Maxwell, G. and Mackay, C. (2008). Application of a systems biology approach to skin allergy risk assessment. Altern Lab Anim 36, 521-556.
69. McCarley, K. D. and Bunge, A. L. (2001). Pharmacokinetic models of dermal absorption. J Pharm Sci 90, 1699-1719.
70. Mclean, A. R. and Michie, C. A. (1995). In vivo estimates of division and death rates of human Tlymphocytes. Proc Natl Acad Sci U S A 92, 3707-3711.
71. Mitragotri, S. (2003). Modeling skin permeability to hydrophilic and hydrophobic solutes based on four permeation pathways. J Controlled Release 86, 69-92.
72. Mitragotri, S., Anissimov, Y. G., Bunge, A. L., et al. (2011). Mathematical models of skin permeability: an overview. Int J Pharm 418, 115-129.
73. Morris, G. P. and Allen, P. M. (2012). How the TCR balances sensitivity and specificity for the recognition of self and pathogens. Nat Immunol 13, 121-128.
74. Murray, J. M., Kaufmann, G. R., Hodgkin, P. D., et al. (2003). Naive Tcells are maintained by thymic output in early ages but by proliferation without phenotypic change after age twenty. Immunol Cell Biol 81, 487-495.
75. Nedorost, S. T. and Cooper, K. D. (2001). The role of patch testing for chemical and protein allergens in atopic dermatitis. Curr Allergy Asthma Rep 1, 323-328.
76. Notman, R. and Anwar, J. (2013). Breaching the skin barrier - insights from molecular simulation of model membranes. Adv Drug Delivery Rev 65, 237-250.
77. OECD (2011). Report of the workshop on using mechanistic information in forming chemical categories. OECD Environment, Health and Safety Publications Series on Testing and Assessment 138, 1-176.
78. OECD (2012a). The Adverse Outcome Pathway for Skin Sensitisation Initiated by Covalent Binding to Proteins. Part 1: Scientific Edvidence. OECD Environment, Health and Safety Publications Series on Testing and Assessment 168, 1-59.
79. OECD (2012b). The Adverse Outcome Pathway for Skin Sensitisation Initiated by Covalent Binding to Proteins. Part 2: Use of the AOP to Develop Chemical Categories and Integrated Assessment and Testing Approaches. OECD Environment, Health and Safety Publications Series on Testing and Assessment 168, 1-46.
80. Ostrov, D. A., Grant, B. J., Pompeu, Y. A., et al. (2012). Drug hypersensitivity caused by alteration of the MHC-presented self-peptide repertoire. Proc Natl Acad Sci U S A 109, 9959-9964.
81. Otto, A., du Plessis, J., and Wiechers, J. W. (2009). Formulation effects of topical emulsions on transdermal and dermal delivery. Int J Cosmet Sci 31, 1-19.
82. Pendlington, R. U., Minter, H. J., Stupart, L., et al. (2008). Development of a modified in vitro skin absorption method to study the epidermal/dermal disposition of a contact allergen in human skin. Cutan Ocul Toxicol 27, 283-294.
83. Perelson, A. and Weisbuch, G. (1997). Immunology for physicists. Rev Mod Phys 69, 1219-1268.
84. Perelson, A. S. (2002). Modelling viral and immune system dynamics. Nat Rev Immunol 2, 28-36.
85. Pickard, C., Louafi, F., McGuire, C., et al. (2009). The cutaneous biochemical redox barrier: a component of the innate immune defenses against sensitization by highly reactive environmental xenobiotics. J Immunol 183, 7576-7584.
86. Potts, R. O. and Guy, R. H. (1992). Predicting skin permeability. Pharm Res 9, 663-669.
87. Reddy, M., Yang, R. S., Andersen, M. E., et al. (2005). Physiologically Based Pharmacokinetic Modeling : Science and Applications. Hoboken, USA: Wiley-Interscience.
88. Rim, J. E., Pinsky, P. M., and van Osdol, W. W. (2009). Multiscale modeling framework of transdermal drug delivery. Ann Biomed Eng 37, 1217-1229.
89. Roberts, D. W. and Natsch, A. (2009). High throughput kinetic profiling approach for covalent binding to peptides: application to skin sensitization potency of Michael acceptor electrophiles. Chem Res Toxicol 22, 592-603.
90. Rotroff, D. M., Wetmore, B. A., Dix, D. J., et al. (2010). Incorporating human dosimetry and exposure into high-throughput in vitro toxicity screening. Toxicol Sci 117, 348-358.
91. Shuey, D. L., Setzer, R. W., Lau, C., et al. (1995). Biological modeling of 5-fluorouracil developmental toxicity. Toxicology 102, 207-13.
92. Simonsson, C., Andersson, S. I., Stenfeldt, A.-L., et al. (2011). Caged fluorescent haptens reveal the generation of cryptic epitopes in allergic contact dermatitis. J Invest Dermatol 131, 1486-1493.
93. Singh, G. and Lavanya, M. (2010). Topical immunotherapy in alopecia areata. Int J Trichol 2, 36-39.
94. Stone, J. D., Chervin, A. S., and Kranz, D. M. (2009). T-cell receptor binding affinities and kinetics: impact on T-cell activity and specificity. Immunology 126, 165-176.
95. Thompson, C. M., Sonawane, B., Barton, H. A., et al. (2008). Approaches for applications of physiologically based pharmacokinetic models in risk assessment. J Toxicol Environ Health Part B Crit Rev 11, 519-547.
96. Tridane, A. and Kuang, Y. (2010). Modeling the interaction of cytotoxic T lymphocytes and influenza virus infected epithelial cells. Math Biosci Eng 7, 171-185.
97. USEPA (2005). Guidelines for carcinogen risk assessment. EPA/630/P-03/001F.
98. Van Eijl, S., Zhu, Z., Cupitt, J., et al. (2012). Elucidation of xenobiotic metabolism pathways in human skin and human skin models by proteomic profiling. PloS One 7, e41721.
99. Vita, R., Zarebski, L., Greenbaum, J. A., et al. (2010). The immune epitope database 2.0. Nucleic Acids Res. 38, D854-862.
100. Vrisekoop, N., den Braber, I., de Boer, A. B., et al. (2008). Sparse production but preferential incorporation of recently produced naive Tcells in the human peripheral pool. Proc Natl Acad Sci U S A 105, 6115-6120.
101. Wang, B., Fujisawa, H., Zhuang, L., et al. (2000). CD4+ Th1 and CD8+ type 1 cytotoxic Tcells both play a crucial role in the full development of contact hypersensitivity. J Immunol 165, 6783-6790.
102. Wang, T.-F., Kasting, G. B., and Nitsche, J. M. (2006). A multiphase microscopic diffusion model for stratum corneum permeability. I. Formulation, solution, and illustrative results for representative compounds. J Pharm Sci 95, 620-648.
103. Wang, C. Y. and Maibach, H. I. (2011). Why minimally invasive skin sampling techniques? A bright scientific future. Cutan Ocul Toxicol 30, 1-6.
104. Watanabe, K. H., Andersen, M. E., Basu, N., et al. (2011). Defining and modeling known adverse outcome pathways: Domoic acid and neuronal signaling as a case study. Environ Toxicol Chem 30, 9-21.
105. Welling, P.G. (1997). Pharmacokinetics: Processes, Mathematics, and Applications. Washington, USA: American Chemical Society.
106. Weltzien, H. U., Moulon, C., Martin, S., et al. (1996). Tcell immune responses to haptens. Structural models for allergic and autoimmune reactions. Toxicology 107, 141-151.
107. Wherry, E. J., Teichgräber, V., Becker, T. C., et al. (2003). Lineage relationship and protective immunity of memory CD8 Tcell subsets. Nat Immunol 4, 225-234.
108. White, J. M. L. (2012). Patch testing: what allergists should know. Clin Exp Allergy 42, 180-185.
109. Wodarz, D. (2006). Killer Cell Dynamics: Mathematical and Computational Approaches to Immunology (Interdisciplinary Applied Mathematics). New York, USA: Springer.
110. Xu, H., DiIulio, N. A., and Fairchild, R. L. (1996). Tcell populations primed by hapten sensitization in contact sensitivity are distinguished by polarized patterns of cytokine production: interferon gamma-producing (Tc1) effector CD8+ Tcells and interleukin (Il) 4/Il-10-producing (Th2) negative regulator. J Exp Med 183, 1001-1012.
111. Yoon, H., Kim, T. S., and Braciale, T. J. (2010). The cell cycle time of CD8+ Tcells responding in vivo is controlled by the type of antigenic stimulus. PloS One 5, e15423.
112. Yoon, M., Campbell, J. L., Andersen, M. E., et al. (2012). Quantitative in vitro to in vivo extrapolation of cell-based toxicity assay results. Crit Rev Toxicol 42, 633-652.
113. Zalko, D., Ja cques, C., Duplan, H., et al. (2011). Viable skin efficiently absorbs and metabolizes bisphenol A. Chemosphere 82, 424-430.